在肯尼亚测试基于药房的不同模式的艾滋病毒暴露前后预防启动和管理:集群随机对照试验的协议
Tabitha Kareithi1, Stephanie D Roche2, Victor Omollo1
1Kenya Medical Research Institute.
Research square
|April 8, 2025
概括
本研究评估了肯尼亚的私人药房提供艾滋病毒暴露前预防 (PrEP) 和暴露后预防 (PEP) 的情况. 它将不同基于药房的交付模式与标准诊所推进行比较,以改善这些艾滋病毒预防服务的采用和延续.
科学领域:
- 公共卫生 公共卫生
- 制药科学 制药科学
- 临床试验 临床试验
背景情况:
- 肯尼亚的私人药房普遍存在,但对于艾滋病毒预防服务,如暴露前预防 (PrEP) 和暴露后预防 (PEP),其利用率不足.
- 与标准的诊所推相比,私人药房在启动和管理PrEP/PEP客户的有效性目前尚不清楚.
- 这项研究旨在了解私营药房如何与公共部门有效合作,以加强艾滋病毒预防.
研究的目的:
- 测试和比较药店提供的PrEP/PEP的各种模型与当前的标准推系统.
- 为了确定药房发起和管理的PrEP/PEP是否会导致更高的吸收和延续率.
- 通过私人药房,为扩大艾滋病毒预防服务的政策和战略提供信息.
主要方法:
- 在肯尼亚中部和西部进行了一项60家药房,四臂集群随机对照试验 (cRCT).
- 药房被随机分配到四个部门:客户持续交付,实施者持续交付,实施者持续+辅导员支持交付和转诊 (控制).
- 主要结局包括PrEP启动和注册后60天的继续,次要结局评估PEP启动,过渡和长期持续.
主要成果:
- 试验正在进行中,注册从2023年6月26日开始.
- 主要分析将每个干预臂的有效性与控制臂进行比较.
- 二次分析将相互比较干预武器,并评估实施结果,如可接受性,可行性和成本.
结论:
- 这项试验将为利用私人药房在肯尼亚提供PrEP和PEP提供关键证据.
- 结果将突出不同基于药房的交付模式的相对有效性,包括那些客户或实施者补贴和顾问支持的药房.
- 预计该研究的结果将指导政策制定和实施战略,通过私营部门的参与来扩大艾滋病毒预防服务.
相关概念视频
Pulmonary Tuberculosis V
157
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
157
Retrovirus Life Cycles
45.4K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
45.4K
Sexually Transmitted Infections
217
Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
217
Pulmonary Tuberculosis I
210
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
210
Drug Administration and Therapy Phases: Overview
391
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
391


